Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
63 Results for "
In vitro stability
" in MedChemExpress (MCE) Product Catalog:
Products (63)
63 Results for "In vitro stability" in MCE Product Catalog:
Cat. No.: HY-169429
CAS No.: 2568903-91-1
Target:
Research Areas:
CHIKV-IN-5 (Compound 26) is a CHIKV inhibitor (EC90 = 0.45 μM). CHIKV-IN-5 inhibits CHIKV replication at a late stage in the virus life cycle by blocking structural protein translation. CHIKV-IN-5 has great in vitro mouse microsomal stability. CHIKV-IN-5 reduces footpad swelling and decreases virus dissemination to other tissues in mice infected with CHIKV .
Cat. No.: HY-146018
CAS No.: 2554622-28-3
HIV-1 inhibitor-23 (compound 12a) is a highly potent HIV-1 non-nucleoside reverse transcriptase inhibitor, with EC50s of 24.9 nM and 10.4 nM for HIV-1 WT and HIV-1 K103N, respectively. HIV-1 inhibitor-23 has low cytotoxicity (CC50 > 221 μM) and a favorable in vitro microsomal stability .
Cat. No.: HY-131445A
Purity: 99.91%
Target:
Research Areas:
SS-RJW100 is a enantiomer of RJW100, which is a racemic agonist of nuclear receptor liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1). SS-RJW100 promotes recruitment of coregulator protein fragments in vitro, recruits the transcriptional intermediary factor 2 (Tif2) coactivator to LRH-1. SS-RJW100 diminishes LRH-1 allosteric activation networks, shows poor thermal stability .
Cat. No.: HY-162600
CAS No.: 2988020-03-5
Target:
Research Areas:
CDK8-IN-15 (Compound 46) is a potent CDK8 inhibitors with an IC50 value of 57 nM. It can enhance the thermal stability of CDK8 along with inhibition against NF-κB and have favourable selectivity across the CDK family and tyrosine kinase. Additionally, it also demostrates a positive effect in vitro psoriasis model induced by TNF-α and alleviats the inflammatory response enhancing the expression of Foxp3 and IL-10, which is promising for research of psoriasis diseases .
Cat. No.: HY-169064
Target:
Research Areas:
HIV-1 inhibitor-75 is a human immunodeficiency virus 1 (HIV-1) inhibitor, with an EC50 value ranging from 0.0039 to 0.338 μM. The binding target of HIV-1 inhibitor-75 is reverse transcriptase, with an IC50 value of 0.055 μM. HIV-1 inhibitor-75 shows good in vitro metabolic stability, exhibiting moderate clearance rates and a longer half-life in human plasma and liver microsomes .
Cat. No.: HY-170887
CAS No.: 3094045-97-0
Target:
Research Areas:
MAO-B-IN-39 (compound11) is a selective monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-39 inhibits MAO-Bwith an IC50 of 3.61 μM. MAO-B-IN-39 demonstrates a potent NRF2 induction capacity. MAO-B-IN-39 exhibits potent anti-inflammatory and neuroprotective activity in OS (oxidative stress)-related in vitro models. MAO-B-IN-39 demonstrates high liver microsomal stability and favorable pharmacokinetics in mice. MAO-B-IN-39 is potential for Parkinson’s disease (PD) research .
Cat. No.: HY-147338S
Synonyms: 5-Methyl-CTP-d3 trisodium
Research Areas:
5-Methylcytidine 5′-triphosphate-d3 trisodium (5-Methyl-CTP-d3 trisodium) is the deuterated-labeled 5-Methylcytidine 5′-triphosphate trisodium (HY-147338A). 5-Methylcytidine 5′-triphosphate trisodium is a modified cytidine triphosphate nucleotide. 5-Methylcytidine 5′-triphosphate trisodium serves as a modified nucleotide substrate for in vitro transcription, partially or completely replacing CTP. 5-Methylcytidine 5′-triphosphate trisodium enhances mRNA stability and translation efficiency, and reduces activation of the innate immune system. 5-Methylcytidine 5′-triphosphate trisodium is used in RNA synthesis-related research .
Cat. No.: HY-147338S2
Synonyms: 5-Methyl-CTP-d8 trisodium
Research Areas:
5-Methylcytidine 5′-triphosphate-d8 trisodium (5-Methyl-CTP-d8 trisodium) is the deuterated-labeled 5-Methylcytidine 5′-triphosphate trisodium (HY-147338A). 5-Methylcytidine 5′-triphosphate trisodium is a modified cytidine triphosphate nucleotide. 5-Methylcytidine 5′-triphosphate trisodium serves as a modified nucleotide substrate for in vitro transcription, partially or completely replacing CTP. 5-Methylcytidine 5′-triphosphate trisodium enhances mRNA stability and translation efficiency, and reduces activation of the innate immune system. 5-Methylcytidine 5′-triphosphate trisodium is used in RNA synthesis-related research .
Cat. No.: HY-147338S1
Synonyms: 5-Methyl-CTP-15N2, 13C trisodium
Research Areas:
5-Methylcytidine 5′-triphosphate- 15N2, 13C trisodium (5-Methyl-CTP- 15N2, 13C trisodium) is the 13C, 15N-labeled 5-Methylcytidine 5′-triphosphate trisodium (HY-147338A). 5-Methylcytidine 5′-triphosphate trisodium is a modified cytidine triphosphate nucleotide. 5-Methylcytidine 5′-triphosphate trisodium serves as a modified nucleotide substrate for in vitro transcription, partially or completely replacing CTP. 5-Methylcytidine 5′-triphosphate trisodium enhances mRNA stability and translation efficiency, and reduces activation of the innate immune system. 5-Methylcytidine 5′-triphosphate trisodium is used in RNA synthesis-related research .
Cat. No.: HY-P11838
Research Areas:
Cat. No.: HY-175413
CAS No.: 2309756-27-0
Target:
Research Areas:
FTAC6 (C6F-TAC) is a lipophobic surfactant. FTAC6 does not solubilize biological membranes as a non-detergent and can substitute for detergents to keep membrane proteins soluble and improves stability after conventional solubilization. FTAC6 can be utilized in in vitro synthesis of membrane proteins .
Cat. No.: HY-183247
Target:
Research Areas:
BRDT-IN-1 is a BRDT-BD1 and BRDT-T inhibitor with BRDT-BD1 IC50 19 nM, Ki 8.8 nM, Ka 1.6 nM, and BRDT-T IC50 56 nM, Ka 5.0 nM. BRDT-IN-1 displays in vitro metabolic stability and limited cellular permeability in MDCK-MDR1 cells. BRDT-IN-1 can be used for the research of multiple myeloma .
Cat. No.: HY-174413
Target:
Research Areas:
A2AAR antagonist 3 is a selective and potent A2A adenosine receptor (A2A AR) antagonist with an IC50 of 1.57 nM. A2AAR antagonist 3 demonstrates high and selective binding affinities to the A2A AR. A2AAR antagonist 3 demonstrates favorable stability in rat liver microsomes in vitro and acceptable pharmacokinetic profiles in vivo. A2AAR antagonist 3 can be used in cancer research.
Cat. No.: HY-W237439
CAS No.: 958712-85-1
SEN205A is a fragment compound that binds to the hydrophobic pocket of human S100B (Kd=0.5-1.0 mM), which is the key region for the interaction of S100B with TRTK-12 and p53, and SEN205A can be displaced from this site by TRTK-12. SEN205A exhibits excellent in vitro ADME properties, including high metabolic stability, chemical stability, and good solubility under physiological pH conditions. SEN205A can serve as a starting fragment for structure-based optimization to develop inhibitors targeting the S100B-p53 protein-protein interaction and investigate the pathogenesis of malignant melanoma .
Cat. No.: HY-145976A
Research Areas:
m7GpppGpG ammonium solution (10 mM) is an unmodified trinucleotide cap analog with enhancer activity. When incorporated into mRNA, it effectively enhances translational efficiency, stability, and protein expression levels of the mRNA. m7GpppGpG ammonium solution (10 mM) can serve as a standard cap analog for in vitro mRNA synthesis to support antigen generation and presentation by dendritic cells, although its expression efficiency in dendritic cells is 20-fold lower than that of the m7GpppApG cap .
Cat. No.: HY-179599
CAS No.: 1448757-02-5
Research Areas:
Dyrk1A-IN-15 is a selective, brain-penetrant and ATP-competitive Dyrk1A inhibitor with a IC50 of 19 nM. Dyrk1A-IN-15 displays high selectivity across a broad kinase panel (specific for DYRK kinases) with nanomolar potency. Dyrk1A-IN-15 impairs neurosphere self-renewal, cell invasion, and EGFR stability in vitro. Dyrk1A-IN-15 inhibits tumor growth and prolongs survival in vivo. Dyrk1A-IN-15 has potential for glioblastoma (GBM) research .
Cat. No.: HY-179600
CAS No.: 2805339-74-4
Research Areas:
Dyrk1A-IN-16 is a selective, brain-penetrant and ATP-competitive Dyrk1A inhibitor with a IC50 of 53 nM. Dyrk1A-IN-16 displays high selectivity across a broad kinase panel (specific for DYRK kinases) with nanomolar potency. Dyrk1A-IN-16 impairs neurosphere self-renewal, cell invasion, and EGFR stability in vitro. Dyrk1A-IN-16 inhibits tumor growth and prolongs survival in vivo. Dyrk1A-IN-16 has potential for glioblastoma (GBM) research .
Cat. No.: HY-182800
Target:
Research Areas:
IBA-11 is a selective CRBN-dependented CK1α molecular glue degrader. IBA-11 binds to the canonical tri-tryptophan pocket of CRBN, forming a ternary complex with CK1α to mediate its degradation. IBA-11 induces CRBN-dependent ubiquitin-proteasome system-mediated degradation of CK1α. IBA-11 exhibits cytotoxicity against cancer cells. IBA-11 demonstrates in vitro metabolic stability in rat liver microsomes and minimal hERG inhibition. IBA-11 can be used for the research of cancer, such as acute myeloid leukemia .
Cat. No.: HY-N12104
CAS No.: 145174-90-9
Synonyms: BMS-182123
Category:
Target:
Cat. No.: HY-187221
Target:
Research Areas:
Anti-SARS-CoV-2 agent prodrug-1 is a double prodrug modified with 5'-ProTide and N 4-propionyl ester, exhibiting anti-SARS-CoV-2 activity (EC50 = 3.22 μM). Anti-SARS-CoV-2 agent prodrug-1 is rapidly converted by esterases into intermediate 4, which has stronger plasma metabolic stability and can be rapidly activated to exert antiviral effects. Anti-SARS-CoV-2 agent prodrug-1 shows anti-SARS-CoV-2 activity in vitro and exhibits low cytotoxicity. Anti-SARS-CoV-2 agent prodrug-1 can be used in studies related to SARS-CoV-2 infection .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
